Table 3.
Characteristics of patients divided by HSP47 expression in cancer cells or number of HSP47-positive fibroblasts in patients with lung cancer
| Characteristics | HSP47 expresion in cancer cells | P value | Number of HSP47-positive fibroblasts | P value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Positive | Negative | High | Low | |||||||||||
| % or (IQR) | [n] | % or (IQR) | [n] | % or (IQR) | [n] | % or (IQR) | [n] | |||||||
| N, no | 67 | 50.4% | 66 | 49.6% | 91 | 68.4% | 42 | 31.6% | ||||||
| Age, median | 69 | (61.0–77.0) | [67] | 74 | (63.0–77.0) | [66] | p = 0.341 | 71 | (63.0–77.0) | [91] | 68.5 | (61.0–77.0) | [42] | p = 0.673 |
| Sex Male, no | 41 | 61.2% | [67] | 46 | 69.7% | [66] | p = 0.363 | 68 | 74.7% | [91] | 19 | 45.2% | [42] | p = 0.015* |
| BMI (kg/m2), median | 22.8 | (20.9–25.0) | [67] | 22.8 | (20.8–24.5) | [66] | p = 0.968 | 22.9 | (21.5–25.0) | [91] | 21.9 | (20.7–24.0) | [42] | p = 0.263 |
| History of smoking, no | 30 | 48.4% | [62] | 17 | 27.9% | [61] | p = 0.026* | 61 | 71.8% | [85] | 15 | 39.5% | [38] | p = 0.012* |
| Brinkman index, median | 877.5 | (455–1515) | [30] | 900 | (562–1200) | [17] | p = 0.322 | 900 | (680–1500) | [61] | 620 | (275–1125) | [15] | p = 0.042* |
| Pulmonary function test | ||||||||||||||
| %VC, median (%) | 111.4 | (102.3–120.4) | [53] | 109 | (98.2–122.3) | [50] | p = 0.611 | 106.4 | (94.0–120.1) | [68] | 115 | (104.1–123.2) | [35] | p = 0.041* |
| FEV1/FVC, median (%) | 73.9 | (64.4–80.3) | [53] | 73.4 | (66.8–77.0) | [50] | p = 0.559 | 73.5 | (64.8–79.0) | [68] | 74.6 | (64.5–77.4) | [35] | p = 0.983 |
| %DLCO, median (%) | 97.6 | (82.1–109.9) | [50] | 80.9 | (65.0–97.1) | [48] | p = 0.001* | 84.3 | (73.4–104.3) | [65] | 93.4 | (77.0–109.1) | [33] | p = 0.371 |
| KL-6, median (U/mL) | 193 | (152.0–303.5) | [37] | 263 | (178–370.3) | [44] | p = 0.020* | 247 | (171–345.5) | [56] | 231 | (167.5–316.5) | [16] | p = 0.377 |
| Adenocarcinoma, no | 60 | 89.6% | [67] | 39 | 59.1% | [66] | p < 0.001* | 57 | 62.6% | [91] | 42 | 100.0% | [42] | p < 0.001* |
| pT classification, no (T3, T4) | 2 | 3.0% | [67] | 6 | 9.1% | [66] | p = 0.165 | 8 | 8.8% | [91] | 0 | 0.0% | [42] | p = 0.557 |
| pN classification, no (N1, N2) | 8 | 11.9% | [67] | 15 | 22.7% | [66] | p = 0.114 | 21 | 23.1% | [91] | 2 | 4.8% | [42] | p = 0.012* |
| pM classification, no (M1) | 1 | 1.5% | [67] | 1 | 1.5% | [66] | p = 1.000 | 2 | 2.2% | [91] | 0 | 0.0% | [42] | p = 1.000 |
| pStage | p = 0.125 | p = 0.025* | ||||||||||||
| I | 56 | 83.6% | [67] | 44 | 66.7% | [66] | 62 | 68.1% | [91] | 38 | 90.5% | [42] | ||
| II | 7 | 10.5% | [67] | 12 | 18.2% | [66] | 15 | 16.5% | [91] | 4 | 9.5% | [42] | ||
| III | 3 | 4.5% | [67] | 9 | 13.7% | [66] | 12 | 13.2% | [91] | 0 | 0.0% | [42] | ||
| IV | 1 | 1.5% | [67] | 1 | 1.5% | [66] | 2 | 2.2% | [91] | 0 | 0.0% | [42] | ||
| Recurrence, no | 13 | 19.4% | [67] | 16 | 24.2% | [66] | p = 0.535 | 27 | 29.7% | [91] | 2 | 4.8% | [42] | p = 0.001* |
| Primary disease death, no | 12 | 17.9% | [67] | 7 | 10.6% | [66] | p = 0.3221 | 15 | 16.5% | [91] | 3 | 7.1% | [42] | p = 0.173 |
| HSP47 expression positive in cancer cells, no | – | – | – | – | 39 | 42.9% | [91] | 28 | 66.7% | [42] | p = 0.015* | |||
| HSP47-positive fibroblasts, no | 71.0 | (28.5–117.5) | [67] | 125 | (74.1–180.6) | [66] | p < 0.001* | – | – | – | – | |||
*; P value < 0.05, Fisher’s exact test or Wilcoxon test
IQR interquartile range, BMI body mass index, VC vital capacity, FEV1/FVC forced expiratory volume in one second/forced vital capacity, DLCO diffusing capacity for carbon monoxide, KL-6 Klebs von den Lungen-6